Lixte Biotechnology Holdings, I
Ticker(s):
LIXT and LIXTW
Country:
Sector & Industry:
Business Overview
LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company’s Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Contact & Other Information
Number of Employees:
3
Website:
,
,
Lixte Biotechnology Holdings, Inc. amended its Clinical Trial Agreement with GEIS, relieving the company of approximately $3,095,000 in financial obligations for the randomized Phase 2 portion of the study.
02/21/2025 | 8-K | 0001493152-25-007865 |Lixte Biotechnology Holdings, Inc. received a notification from Nasdaq stating that it did not meet the terms of the extension to regain compliance with the minimum stockholders’ equity requirement, and the company intends to appeal this decision.